<div id="readability-page-1"><p>Edgestream Partners L.P. bought a new stake in  Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 53,175 shares of the company's stock, valued at approximately $763,000. Edgestream Partners L.P. owned 0.06% of Pediatrix Medical Group as of its most recent filing with the Securities and Exchange Commission.</p><ul><li>Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum</li></ul><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. Boston Partners boosted its holdings in  Pediatrix Medical Group by 1.3% in the first quarter. Boston Partners now owns 1,981,889 shares of the company's stock valued at $27,990,000 after acquiring an additional 25,536 shares during the last quarter.  American Century Companies Inc. lifted its position in  Pediatrix Medical Group by 28.6% during the 2nd quarter. American Century Companies Inc. now owns 1,931,867 shares of the company's stock valued at $27,722,000 after purchasing an additional 430,029 shares during the period.  Invesco Ltd. boosted its stake in shares of  Pediatrix Medical Group by 9.3% in the 1st quarter. Invesco Ltd. now owns 863,269 shares of the company's stock valued at $12,509,000 after purchasing an additional 73,157 shares during the last quarter.  Bridgeway Capital Management LLC grew its position in shares of  Pediatrix Medical Group by 1.7% during the 1st quarter. Bridgeway Capital Management LLC now owns 554,452 shares of the company's stock worth $8,034,000 after buying an additional 9,007 shares during the period.  Finally, Nuveen LLC bought a new stake in shares of  Pediatrix Medical Group during the first quarter worth approximately $8,024,000. Institutional investors own  97.71% of the company's stock. </p><h2>Pediatrix Medical Group Stock Down 0.7%</h2><p>MD stock opened at $22.14 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.83 and a quick ratio of 1.83. The stock has a market capitalization of $1.90 billion, a P/E ratio of 11.65 and a beta of 0.77. Pediatrix Medical Group, Inc. has a fifty-two week low of $11.84 and a fifty-two week high of $24.99. The business has a 50-day moving average of $19.94 and a 200-day moving average of $16.47. </p><ul><li>MarketBeat Week in Review – 08/18 - 08/22</li></ul><p>Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.21. Pediatrix Medical Group had a return on equity of 20.45% and a net margin of 8.44%.The business had revenue of $492.88 million for the quarter, compared to analyst estimates of $476.45 million. During the same quarter last year, the firm earned $0.44 EPS. Pediatrix Medical Group's revenue for the quarter was down 3.6% compared to the same quarter last year.  On average, sell-side analysts anticipate that  Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year. </p><h2>Insider Activity</h2><p>In other Pediatrix Medical Group news, Director Michael A. Rucker sold 10,478 shares of the business's stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $23.00, for a total transaction of $240,994.00. Following the transaction, the director owned 59,101 shares of the company's stock, valued at $1,359,323. The trade was a 15.06% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, Director Laura A. Linynsky sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $21.65, for a total value of $216,500.00. Following the transaction, the director directly owned 32,232 shares in the company, valued at $697,822.80. The trade was a 23.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own  0.90% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Medtronic: The Opportunity Gets Healthier for Income Investors</li></ul><p>A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of Pediatrix Medical Group from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, October 4th. Leerink Partners raised their price target on Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a &#34;market perform&#34; rating in a research report on Friday, September 5th. Weiss Ratings  reiterated a &#34;hold (c+)&#34; rating on shares of Pediatrix Medical Group in a report on Monday, December 1st. Zacks Research upgraded Pediatrix Medical Group from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Friday, November 21st. Finally, UBS Group upped their price target on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, November 5th. One equities research analyst  has rated the stock with a Strong Buy rating, one  has issued  a Buy rating and four have assigned  a Hold rating to the stock. Based on data from MarketBeat, Pediatrix Medical Group presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $21.00.</p><p><b>Get Our Latest Report on MD</b></p><h2>Pediatrix Medical Group Company Profile</h2> (Free Report)<p>Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Pediatrix Medical Group</li><li>Do ETFs Pay Dividends? What You Need to Know</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li><li>Consumer Staples Stocks, Explained</li><li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li><li>How to Know Which Cryptocurrency to Buy: A Guide for Investors</li><li>MarketBeat Week in Review – 12/1 - 12/5</li></ul><p><strong>Want to see what other hedge funds are holding MD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pediatrix Medical Group, Inc. (NYSE:MD - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1E?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1E"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pediatrix Medical Group Right Now?</h2><p>Before you consider Pediatrix Medical Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.</p><p>While Pediatrix Medical Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Edgestream Partners L.P. invested in Pediatrix Medical Group, buying 53,175 shares worth $763,000. Other investors adjusted their holdings, with Boston Partners, American Century Companies, and others increasing their stakes. Pediatrix reported strong earnings, surpassing analyst expectations, and received positive ratings from Wall Street analysts. Corporate insiders sold shares, reducing their positions. The stock has a market cap of $1.90 billion and a P/E ratio of 11.65. Analysts forecast growth, with a strong-buy rating from Wall Street Zen.</p>

Edgestream Partners L.P. Makes New Investment in Pediatrix Medical Group, Inc. $MD